| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
Envafolimab manufacturers
- Envafolimab
-
- $213.00
-
2026-05-12
- CAS:2102192-68-5
- Purity: 95.00%
- Supply Ability: 10g
|
| | Envafolimab Basic information |
| Product Name: | Envafolimab | | Synonyms: | Envafolimab;Research Grade Envafolimab (DHJ70104);Envafolimab (anti-PD-L1);Research Grade Envafolimab | | CAS: | 2102192-68-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Envafolimab Structure]() |
| | Envafolimab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow |
| | Envafolimab Usage And Synthesis |
| Uses | Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25nM. Envafolimab has the potential for the research of solid tumors[1][2][3]. | | in vivo | Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72h in NOD-SCID mice (A375 cells)[3]. | | References | [1] Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021 Sep;26(9):e1514-e1525. DOI:10.1002/onco.13817
[2] Akinleye A, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12(1):92. DOI:10.1186/s13045-019-0779-5
[3] Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017 Mar 7;3:17004. DOI:10.1038/celldisc.2017.4 |
| | Envafolimab Preparation Products And Raw materials |
|